- Aug 08, 2023 Foghorn Therapeutics Announces Chief Medical Officer Succession
- Aug 04, 2023 Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
- Jun 28, 2023 Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
- Jun 07, 2023 Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
- Jun 05, 2023 Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
- May 08, 2023 Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
- Apr 25, 2023 Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
- Apr 24, 2023 Foghorn Therapeutics Provides an Update on FHD-609
- Apr 10, 2023 Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting
- Apr 06, 2023 Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
Displaying 31 - 40 of 93